PANCREATIC CANCER: ONE OF THE GREATEST CHALLENGES OF CONTEMPORARY MEDICINE
Abstract
.
Downloads
Download data is not yet available.
References
1. Hruban, R.H., et al., Why is pancreatic cancer so deadly? The pathologist’s view. J Pathol, 2019. 248(2): p. 131-141.
2. Rawla, P., T. Sunkara, and V. Gaduputi, Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol, 2019. 10(1): p. 10-27.
3. Ilic, M. and I. Ilic, Epidemiology of pancreatic cancer. World J Gastroenterol, 2016. 22(44): p. 9694-9705.
4. Marques da Costa, P., et al., Twenty-Five Years of Increasing Mortality From Pancreatic Cancer in Portugal. Pancreas, 2020. 49(1): p. e2-e3.
5. Tempero, M.A., NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw, 2019. 17(5.5): p. 603-605.
6. Basturk, O., et al., A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol, 2015. 39(12): p. 1730-41.
7. Strobel, O., et al., Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol, 2019. 16(1): p. 11-26.
8. Bateni, S.B., et al., Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. JAMA Surg, 2019. 154(10): p. e193019.
9. Gani, F., et al., Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. J Gastrointest Surg, 2017. 21(9):p. 1411-1419.
10. Conroy, T., et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med, 2018. 379(25):p. 2395-2406.
11. Mizrahi, J.D., et al., Pancreatic cancer. Lancet, 2020. 395(10242): p. 2008-2020.
12. Pishvaian, M.J., et al., Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res, 2018. 24(20): p. 5018-5027.
13. Collisson, E.A., et al., Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol, 2019. 16(4): p. 207-220.
14. O’Reilly, E.M., et al., Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol, 2019.
15. Thompson, E.D., et al., The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol, 2020. 33(12): p. 2544-2563.
2. Rawla, P., T. Sunkara, and V. Gaduputi, Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol, 2019. 10(1): p. 10-27.
3. Ilic, M. and I. Ilic, Epidemiology of pancreatic cancer. World J Gastroenterol, 2016. 22(44): p. 9694-9705.
4. Marques da Costa, P., et al., Twenty-Five Years of Increasing Mortality From Pancreatic Cancer in Portugal. Pancreas, 2020. 49(1): p. e2-e3.
5. Tempero, M.A., NCCN Guidelines Updates: Pancreatic Cancer. J Natl Compr Canc Netw, 2019. 17(5.5): p. 603-605.
6. Basturk, O., et al., A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. Am J Surg Pathol, 2015. 39(12): p. 1730-41.
7. Strobel, O., et al., Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol, 2019. 16(1): p. 11-26.
8. Bateni, S.B., et al., Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer. JAMA Surg, 2019. 154(10): p. e193019.
9. Gani, F., et al., Hospital Volume and the Costs Associated with Surgery for Pancreatic Cancer. J Gastrointest Surg, 2017. 21(9):p. 1411-1419.
10. Conroy, T., et al., FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med, 2018. 379(25):p. 2395-2406.
11. Mizrahi, J.D., et al., Pancreatic cancer. Lancet, 2020. 395(10242): p. 2008-2020.
12. Pishvaian, M.J., et al., Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res, 2018. 24(20): p. 5018-5027.
13. Collisson, E.A., et al., Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol, 2019. 16(4): p. 207-220.
14. O’Reilly, E.M., et al., Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol, 2019.
15. Thompson, E.D., et al., The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go. Mod Pathol, 2020. 33(12): p. 2544-2563.
Published
2021-01-20
How to Cite
PAULINO, Jorge.
PANCREATIC CANCER: ONE OF THE GREATEST CHALLENGES OF CONTEMPORARY MEDICINE.
Revista Portuguesa de Cirurgia, [S.l.], n. 49, p. 110-113, jan. 2021.
ISSN 2183-1165.
Available at: <https://revista.spcir.com/index.php/spcir/article/view/873>. Date accessed: 19 apr. 2024.
doi: https://doi.org/10.34635/rpc.873.
Section
Reflections
